<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04645212</url>
  </required_header>
  <id_info>
    <org_study_id>ADVM-022-07</org_study_id>
    <nct_id>NCT04645212</nct_id>
  </id_info>
  <brief_title>Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]</brief_title>
  <official_title>A Long-term Study of ADVM-022 in Neovascular (Wet) AMD - OPTIC Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adverum Biotechnologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adverum Biotechnologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and&#xD;
      efficacy of ADVM-022 gene therapy product, in subjects with neovascular, or exudative (wet),&#xD;
      age-related macular degeneration (nAMD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product developed for the treatment of&#xD;
      neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is a serious condition&#xD;
      and the leading cause of blindness in the elderly. The available therapies for treating wet&#xD;
      AMD require life-long intravitreal (IVT) injections every 4-12 weeks to maintain efficacy. A&#xD;
      one-time IVT administration of ADVM-022 has the potential to treat wet AMD by providing&#xD;
      durable expression of therapeutic levels of intraocular anti-VEGF protein (aflibercept) and&#xD;
      maintaining the vision of patients. ADVM-022 is designed to reduce the current treatment&#xD;
      burden which often results in undertreatment and vision loss in patients with wet AMD&#xD;
      receiving anti-VEGF therapy in clinical practice.&#xD;
&#xD;
      ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and&#xD;
      efficacy of ADVM-022 gene therapy product, in subjects with neovascular, or exudative (wet),&#xD;
      age-related macular degeneration (nAMD).&#xD;
&#xD;
      To evaluate potential long-term outcomes of ADVM-022, the OPTIC-EXT will follow subjects&#xD;
      previously treated in the OPTIC parent study (Clinical Protocol No. ADVM-022-01 [OPTIC]&#xD;
      (NCT03748784)). Subjects will roll over from the OPTIC parent study and will be followed for&#xD;
      3 additional years, following completion of the preceding 2-year assessment period in the&#xD;
      OPTIC parent study. There is no investigational treatment administered in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 14, 2020</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Type, severity and incidence of ocular and systemic adverse events (AEs).</measure>
    <time_frame>156 weeks</time_frame>
    <description>Type, severity and incidence of ocular and systemic adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in best corrected visual acuity (BCVA) from baseline, over time</measure>
    <time_frame>156 weeks</time_frame>
    <description>Change in best corrected visual acuity (BCVA) from baseline, over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in central subfield thickness (CST) and macular volume from baseline, over time</measure>
    <time_frame>156 weeks</time_frame>
    <description>Mean change in central subfield thickness (CST) and macular volume from baseline, over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects requiring supplemental aflibercept over time</measure>
    <time_frame>156 weeks</time_frame>
    <description>Percentage of subjects requiring supplemental aflibercept over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of supplemental aflibercept injections over time</measure>
    <time_frame>156 weeks</time_frame>
    <description>Mean number of supplemental aflibercept injections over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects without intraretinal fluid (IRF) by spectral domain optical coherence tomography (SD-OCT), over time</measure>
    <time_frame>156 weeks</time_frame>
    <description>Percentage of subjects without intraretinal fluid (IRF) by spectral domain optical coherence tomography (SD-OCT), over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects without subretinal fluid (SRF) by SD-OCT over time</measure>
    <time_frame>156 weeks</time_frame>
    <description>Percentage of subjects without subretinal fluid (SRF) by SD-OCT over time</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Wet Age-related Macular Degeneration</condition>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Subjects with wet AMD who received any dose of ADVM-022 in a prior clinical study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ADVM-022</intervention_name>
    <description>Long term follow-up of subjects that received ADVM-022</description>
    <arm_group_label>1</arm_group_label>
    <other_name>AAV.7m8-aflibercept</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  Subjects who received ADVM-022 at any dose in the OPTIC study&#xD;
&#xD;
          -  Up to 30 subjects from all cohorts of OPTIC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who received a single dose of ADVM-022 at any dose in the OPTIC study&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Clark, MD, MS</last_name>
    <role>Study Director</role>
    <affiliation>Adverum Biotechnologies, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Adverum Clinical Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adverum Clinical Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adverum Clinical Site</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adverum Clinical Site</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adverum Clinical Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adverum Clinical Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adverum Clinical Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adverum Clinical Site</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adverum Clinical Site</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 20, 2020</study_first_submitted>
  <study_first_submitted_qc>November 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2020</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Choroidal Neovascularization</keyword>
  <keyword>ADVM-022</keyword>
  <keyword>OPTIC Study</keyword>
  <keyword>CNV</keyword>
  <keyword>ADVM-022-01</keyword>
  <keyword>ADVM-022-07</keyword>
  <keyword>AAV.7m8</keyword>
  <keyword>Anti-VEGF therapy</keyword>
  <keyword>Blindness</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>Aflibercept (Eylea)</keyword>
  <keyword>Age-Related Macular Degeneration</keyword>
  <keyword>Wet Macular Degeneration</keyword>
  <keyword>Retinal Degeneration</keyword>
  <keyword>Retinal Diseases</keyword>
  <keyword>Eye Diseases</keyword>
  <keyword>AAV Vector</keyword>
  <keyword>Adverum</keyword>
  <keyword>wAMD</keyword>
  <keyword>AMD</keyword>
  <keyword>wet AMD</keyword>
  <keyword>nAMD</keyword>
  <keyword>OPTIC Extension</keyword>
  <keyword>OPTIC-EXT</keyword>
  <keyword>Long-term Follow Up</keyword>
  <keyword>Long-term Extension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

